electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2025, Financial Results on Thursday, March 19, 2026
Rhea-AI Summary
electroCore (Nasdaq: ECOR) will report fourth quarter and full year 2025 financial results after market close on Thursday, March 19, 2026. Management will host a webinar at 4:30 PM EDT to review results and take investor questions; dial-in and webinar access details are provided.
Positive
- None.
Negative
- None.
News Market Reaction – ECOR
On the day this news was published, ECOR declined 3.07%, reflecting a moderate negative market reaction. Argus tracked a trough of -10.6% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $51M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ECOR fell 8.91% while momentum scanner shows peer MODD up 10.599999874830246%; broader peers show mixed moves, pointing to a stock-specific move rather than a sector-wide trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 21 | PTSD study launch | Positive | +10.2% | Announced PTSD study using gammaCore Sapphire with up to 40 adult participants. |
| Jan 20 | Preliminary 2025 update | Positive | -3.6% | Preliminary 2025 revenue guidance showing ~26% growth to about $31.8–$32.0M. |
| Dec 2 | TAC-STIM performance data | Positive | -0.4% | Peer‑reviewed TAC‑STIM study showing significant mood and performance improvements. |
| Nov 10 | Conference participation | Neutral | +1.3% | Announcement of participation in Canaccord Genuity MedTech and Digital Health forum. |
| Nov 5 | Q3 2025 earnings | Positive | +23.2% | Record Q3 2025 net sales growth and raised full-year 2025 revenue guidance. |
Recent news often involved positive clinical and financial updates, with three aligned positive price reactions and two instances where favorable news coincided with flat or negative moves.
Over the past months, ECOR reported record Q3 2025 net sales and raised 2025 revenue guidance on Nov 05, 2025, which saw a 23.21% gain. A preliminary 2025 business update on Jan 20, 2026 guided to ~26% revenue growth but the stock fell 3.64%. Clinical and research updates on TAC‑STIM and PTSD applications showed significant performance and symptom improvements, yet price reactions were mixed. This earnings-date announcement follows a period of growing revenues but persistent net losses.
Regulatory & Risk Context
An effective S-3 resale registration filed on Oct 03, 2025 covers up to 762,508 shares for selling stockholders. The company is not selling securities under this shelf and will not receive proceeds from these resales, though it bears registration expenses.
Market Pulse Summary
This announcement sets the timeline for electroCore’s Q4 and full-year 2025 release on March 19, 2026, with management hosting a 4:30 PM EDT webinar. It follows prior updates that showed revenue growth but continuing net losses and a complex capital structure. Investors may focus on final 2025 revenue, cash levels, and any revisions to guidance for 2026. Monitoring subsequent SEC filings and management commentary from the call will be important for assessing operational progress.
AI-generated analysis. Not financial advice.
ROCKAWAY, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the fourth quarter and full year ended December 31, 2025, after the close of the market on Thursday, March 19, 2026.
Management will host a webinar at 4:30 PM EDT to review the financial results and answer questions. Investors can access the webinar using the details below:
Thursday, March 19, 4:30 PM EDT
Dial-In: (646) 931-3860
Webinar ID: 886 9421 4883
Passcode: 014212
Registration Link: Click here to participate and ask questions on the call.
About electroCore, Inc.
electroCore, Inc. and its subsidiaries (“electroCore” or the “Company”) is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products to treat chronic pain syndromes through non-invasive neuromodulation technology are gammaCore non-invasive vagus nerve stimulation, or nVNS, and the Quell® Fibromyalgia. Additionally, the Company commercializes its handheld and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Contact
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
When will electroCore (ECOR) release Q4 and full-year 2025 results?
How can investors join the electroCore (ECOR) earnings webinar on March 19, 2026?
What are the dial-in details for the electroCore (ECOR) March 19, 2026 webinar?
Will electroCore (ECOR) allow questions during the March 19, 2026 results call?
Where can I register to participate in the electroCore (ECOR) March 19, 2026 earnings call?
